New Clinical Data Highlight Povorcitinib’s Potential to Achieve High-Threshold Lesion Clearance in HS

Living with the constant pain and physical burden of hidden wounds can make everyday life feel like an uphill battle for people managing hidradenitis suppurativa (HS).

At the Winter Clinical Miami 2026 meeting, researchers shared promising results from 2 posters detailing how an investigational oral therapy, povorcitinib, addressed both the physical lesions and the profound quality of life challenges associated with this chronic inflammatory condition. The data, drawn from the phase 3 STOP-HS1¹ and STOP-HS2² trials, indicated that this selective Janus kinase 1 (JAK1) inhibitor provided early and sustained relief for participants, many of whom had been struggling with "very severe" symptoms for a decade.

Across both studies, a daily tablet of either 45 mg or 75 mg of povorcitinib helped reduce the count of painful abscesses, nodules, and draining tunnels while simultaneously improving participants' emotional well-being and their ability to perform daily activities.

Objective Reductions in Complex Skin Lesions¹

Treating the physical manifestations of HS—which include recurrent nodules and irreversible tissue damage from draining tunnels—has historically been difficult for clinicians and people living with the disease. This post hoc analysis followed 1227 adults who had been diagnosed with HS for an average of approximately 10 years. The study population was characterized by a high disease burden; participants had a median age in their mid-to-late 30s, and a significant portion were categorized as Hurley stage III, the most severe form of the condition. At baseline, participants presented with a mean of 11.1 to 13.0 abscesses and inflammatory nodules and 2.5 to 3.0 draining tunnels. Additionally, 35.1% to 39.4% of participants had previously used biologic therapies without success, and roughly 20% had undergone prior excision surgeries for their HS.

The researchers found that povorcitinib was associated with rapid improvements in all lesion types. By week 12, the 75-mg dose showed particularly strong results in clearing the most difficult-to-treat lesions, with 12% to 57% of participants achieving a 100% reduction in draining tunnels. High-threshold responses for abscesses were also notable; 22% to 62% of those on the 75-mg dose achieved total clearance by week 12. These clinical benefits continued to grow through week 24, suggesting that longer treatment duration could lead to even greater clearance.

As the researchers noted, "These results show that povorcitinib can help improve HS symptoms no matter how severe the disease was at the start.” However, the study was limited by its nature as a post hoc analysis using an interim data cut from ongoing trials.

Restoring Quality of Life and Daily Functioning²

Beyond physical pain, HS often causes significant psychological distress due to symptoms like odor, drainage, and fatigue. To measure these impacts, researchers utilized the Hidradenitis Suppurativa Quality of Life (HiSQoL) questionnaire, where scores ranging from 24 to 68 indicate "very severe" impairment. At the start of the trial, participants reported mean total HiSQoL scores between 30.9 and 32.5. Their baseline scores in subdomains—such as symptoms (8.6-8.9), psychosocial health (7.9-8.7), and activities/adaptations (14.2-15.2)—further highlighted the deep emotional and functional toll of the condition.

The analysis demonstrated that povorcitinib led to meaningful improvements in quality of life as early as week 3. For instance, participants in the 75-mg group saw a percentage reduction in their HiSQoL scores ranging from 22.1% to 30.7% by the third week, compared with a range of 1.2% to –7.8% for those on the placebo. By week 24, over 50% of participants in several treatment arms reached the minimal clinically important difference (MCID), which required at least a 21-point reduction in their total score. Specifically, in the 75-mg group at week 24, the MCID for the psychosocial subdomain was achieved by up to 60.3% of participants. The authors concluded that "these findings support the potential of povorcitinib to provide early and meaningful QoL benefits in patients with moderate to severe HS.”

One identified limitation was a relatively high placebo response in the psychosocial subdomain, which the authors suggested might have been influenced by the frequent professional care and attention participants received during the clinical trial. Despite this, the consistent trend across both studies suggested that the medication helped people feel less anxious and more comfortable in their regular routines.

References

1. Hsiao JL, Porter ML, Martorell A, et al. Povorcitinib effect on hidradenitis suppurativa lesion types. Presented at: Winter Clinical Miami 2026; February 27-March 1, 2026; Aventura, FL.

2. Sayed CJ, Porter ML, Martorell A, et al. HiSQoL improvements in patients with moderate to severe hidradenitis suppurativa. Presented at: Winter Clinical Miami 2026; February 27-March 1, 2026; Aventura, FL.